Combination of Tratuzumab and Chemotherapy Yields Better Results for Breast Cancer
A recent meta-analysis of five major breast cancer trials has confirme...At the ESMO Conference Lugano Issa Dahabreh from the University...All the trials compared disease-free survival overall survival and...Up to a quarter of all breast cancers express large amounts of t...The results showed that combining trastuzumab with chemotherapy ...
A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.
At the ESMO Conference Lugano, Issa Dahabreh from the University of Athens reported the results of a meta-analysis of 5 trials involving more than 13,000 women whose breast cancer was amenable to surgery.
All the trials compared disease-free survival, overall survival and the risk of locoregional and distant recurrence of breast cancer in women given adjuvant chemotherapy alone or chemotherapy plus trastuzumab, after breast surgery.
Up to a quarter of all breast cancers express large amounts of the HER2 protein or carry multiple copies of the HER2 gene. Those cancers tend to be associated with aggressive disease, a higher likelihood of recurrence and a decreased response to treatment. Trastuzumab is a monoclonal antibody that directly targets part of the HER2 tyrosine kinase receptor.
The results showed that combining trastuzumab with chemotherapy results in a -34% reduction in mortality and a 38% increase in disease-free survival, Dahabreh said. Those survival benefits were accompanied by decreases in the risk of both locoregional and distant recurrences of the cancer.
Taken together, these results confirm that the administration of trastuzumab in combination with chemotherapy should be the standard choice for the treatment of women with HER2 positive early stage disease, especially those with limited cardiovascular comorbidities, Dahabreh said.
This is the first meta-analysis of current published trials on the adjuvant use of trastuzumab. The results are of great clinical value since they indicate that treatment with trastuzumab results in major survival benefit in women with an aggressive disease subtype.
The level of effectiveness demonstrated by this ana '"/>
(Date:12/4/2009)... are recruited annually to participate in clinical...ch Protection (AHRP), and most will be compensated...tions view payments to volunteers as compensation ...ential risks related to participating in the exper...e a very different view of clinical trial compensa...
(Date:12/4/2009)...it consumption leads to success, study finds , ...reased exercise, reduced soda consumption and self...rol strategies for adolescents, a new study shows....heir weight-control strategies and lifestyle habit... had not. The responses were grouped into four cat...
(Date:12/4/2009)...r at-risk patient groups , , FRIDAY, Dec...rticularly Ewing sarcomas and central nervous syst... researchers have found. , The study authors an... most common pediatric cancers who were enrolled i...searchers found that the overall cancer recurrence...
(Date:12/4/2009)...y hesitate to take breast cancer drug, study finds...Worries about side effects are a major reason why ...breast cancer are willing to take the drug tamoxif... In an effort to inform women about the risks and ...ty of Michigan Comprehensive Cancer Center created...
(Date:12/4/2009)...la., Dec. 4 Today, seven of Florid...in improving the health of Florida,s uninsured and...Florida,s 2009 Sapphire Award ceremony. ,, The ...hat recognizes and promotes organizations that hav...parities within their communities. ,, Honorees ...
...tional AIDS Vaccine Initiative (IAVI) together wit...have announced a public-private partnership to dev...uman primate adenovirus vector technology was deri...GSK.
According to the agreement, IAVI and GS...
...vening the U.S. Food and Drug Administration order...beling as several cases have been reported to caus...ed that all consumers should stop taking impotency...s.
This move was followed by an announcemen...
... provide quick relief from post pregnancy depressi...women who may be more vulnerable to this type of d...he condition. However a recent study by the resear... depression but the treatment meted out to the pre...
...h teams working independently have identified how ...lls to cause infections.
Hendra virus belongs...wn to cause an outbreak of respiratory and neurolo...s, mostly in men.
Researchers have found that...
...hod to reduce the risk of deaths from advanced pro... method of screening. A recent study suggests that...aths.
Prostate cancer is the most frequently ...ady spread to other organs. PSA blood test is a si...
... of two human clinical trials support the enhance...ges using its novel technology which will interest... its bioavailability, or the body's absorption of ...e emulsifiers and solvents to trap water droplets ...
(Date:12/4/2009)...wswire-FirstCall/ -- The U.S. Food and Drug Admi...nzapine) in tablet form as an option for the treat...associated with bipolar I disorder in adolescents ...abel states that clinicians should take into consi...nd hyperlipidemia in adolescents compared to adult...
(Date:12/4/2009)...PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc...st an investor teleconference and webcast. Princi...ons surrounding carfilzomib in relapsed and/or ref...American Society of Hematology (ASH) Annual Meetin.... CT/10:00 a.m. ET on Monday, December 7, 2009. T...
(Date:12/4/2009)...4 Chemistry World rec... Pharmaceutical Research and Manufacturers of Amer...ccines in development for HIV/AIDS and related con...roducts in development include 23 vaccines and 54 ...al trials or awaiting approval by the U.S. Food an...
...IS, and TORONTO, Sept. 17 Sanofi pasteur, the,vac...ced today that it is,sponsoring a Phase II clinica...ch to high risk and advanced-stage melanoma -- an ...ited treatment options. Patients are being,enrolle...ed MEL11, will,investigate the safety and efficacy...
...EVA, Sept. 17 Merck Serono, a division of Merck,K...ent enrollment has been,completed in the REFLEX tr...osis). This randomized, double-blind, placebo-cont...o evaluate the therapeutic,benefit of Rebif(R) (in...tiple sclerosis (MS) in people with a first clinic...
HCS INTERACTANT Application Financial System Solutions
Infinity Amylase CNPG3 (Liquid)
Infinity Uric Acid (Powder)
...owder reagent once reconstituted offers the labora...y to help maximize laboratory productivity, minimi...und time. The proprietary technology of the Infini...elf life and stability once reconstituted that wil...